The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N06 | Psychoanaleptics | |
| 3 | N06D | Anti-dementia drugs | |
| 4 | N06DX | Other anti-dementia drugs | |
| 5 | N06DX01 | Memantine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 20 mg |
| Active Ingredient | Description | |
|---|---|---|
| Memantine |
Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist. It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| AXURA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| EBIXA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| EBIXA Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
| NEMDATINE Film-coated tablets | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
